Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer-Reference-Cited by-同舟云学术

Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer

Published:2019-04 Issue:4 Volume:25 Page:641-655
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Malehmir Mohsen,Pfister Dominik,Gallage Suchira,Szydlowska Marta^ORCID,Inverso Donato^ORCID,Kotsiliti Elena,Leone Valentina,Peiseler Moritz,Surewaard Bas G. J.,Rath Dominik,Ali Adnan,Wolf Monika Julia,Drescher Hannah,Healy Marc E.,Dauch Daniel,Kroy Daniela,Krenkel Oliver,Kohlhepp Marlene,Engleitner Thomas,Olkus Alexander,Sijmonsma Tjeerd,Volz Julia,Deppermann Carsten^ORCID,Stegner David^ORCID,Helbling Patrick^ORCID,Nombela-Arrieta César^ORCID,Rafiei Anahita,Hinterleitner Martina^ORCID,Rall Marcel,Baku Florian,Borst Oliver,Wilson Caroline L.,Leslie Jack,O’Connor Tracy,Weston Christopher J.^ORCID,Adams David H.,Sheriff Lozan,Teijeiro Ana,Prinz Marco,Bogeska Ruzhica,Anstee Natasha,Bongers Malte N.^ORCID,Notohamiprodjo Mike,Geisler Tobias,Withers Dominic J.^ORCID,Ware Jerry^ORCID,Mann Derek A.,Augustin Hellmut G.,Vegiopoulos Alexandros,Milsom Michael D.,Rose Adam J.^ORCID,Lalor Patricia F.,Llovet Josep M.^ORCID,Pinyol Roser,Tacke Frank,Rad Roland,Matter Matthias^ORCID,Djouder Nabil,Kubes Paul^ORCID,Knolle Percy A.^ORCID,Unger Kristian,Zender Lars,Nieswandt Bernhard,Gawaz Meinrad^ORCID,Weber Achim^ORCID,Heikenwalder Mathias^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/s41591-019-0379-5.pdf

Reference85 articles.

1. Fleet, S. E., Lefkowitch, J. H. & Lavine, J. E. Current concepts in pediatric nonalcoholic fatty liver disease. Gastroenterol. Clin. North Am. 46, 217–231 (2017).

2. European Association for the Study of the Liver, European Association for the Study of Diabetes & European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 64, 1388–1402 (2016).

3. Younossi, Z. et al. Global perspectives on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Hepatology https://doi.org/10.1002/hep.30251 (2018).

4. Brunt, E. M. et al. Nonalcoholic fatty liver disease. Nat. Rev. Dis. Primers 1, 15080 (2015).

5. Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M. & Sanyal, A. J. Mechanisms of NAFLD development and therapeutic strategies. Nat. Med. 24, 908–922 (2018).

Cited by 288 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Improved Liver Intravital Microscopic Imaging Using a Film-Assisted Stabilization Method;ACS Sensors;2024-09-03

2. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD);Journal of Hepatology;2024-09

3. Novel Small-Molecule Atypical Chemokine Receptor 3 Agonists: Design, Synthesis, and Pharmacological Evaluation for Antiplatelet Therapy;Journal of Medicinal Chemistry;2024-08-08

4. Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside;Experimental Hematology & Oncology;2024-08-01

5. Evaluation of artificial intelligence‐assisted morphological analysis for platelet count estimation;International Journal of Laboratory Hematology;2024-07-20